Bo Cumbo, AavantiBio CEO

Scoop: A small gene ther­a­py biotech, flush with ex-Sarep­ta and blue­bird lead­ers, guts CMC

En route to en­ter­ing the clin­ic with its first AAV-based gene ther­a­py for a rare neu­ro­mus­cu­lar dis­ease, Aa­van­tiBio has let go of 30 em­ploy­ees, …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.